Phase I trial of interferon-γ (IFN-γ) retroviral vector administered intratumorally to patients with metastatic melanoma

Cancer Gene Therapy

Volumn 6, Issue 4, 1999, Pages 322-330

  Nemunaitis, John ^a   Fong, Timothy ^b   Robbins, Joan M ^b   Edelman, Gerald ^a   Edwards, Wilson ^b   Paulson, R Steven ^a   Bruce, Janet ^c   Ognoskie, Nadine ^a   Wynne, Dee ^b   Pike, Marilyn ^b   Kowal, Kieron ^b   Merritt, James ^b   Ando, Dale ^b  

^a University of South Carolina   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Interferon ; Melanoma; Retroviral vector

Indexed keywords

GAMMA INTERFERON; VIRUS DNA;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; FEMALE; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; INTRALESIONAL DRUG ADMINISTRATION; MALE; MELANOMA; METASTASIS; MIDDLE AGED; PATHOLOGY; PHASE 1 CLINICAL TRIAL; RETROVIRUS; SURVIVAL; TREATMENT OUTCOME; VIRUS DNA CELL DNA INTERACTION;

ADULT; AGED; DNA, VIRAL; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; INJECTIONS, INTRALESIONAL; INTERFERON TYPE II; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; RETROVIRIDAE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRUS INTEGRATION;

EID: 0033163182     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700019     Document Type: Article

References (55)

1. Welander CE, Homesley HD, Reich SD, Levin EA. A phase II study of the efficacy of recombinant interferon γ in relapsing ovarian adenocarcinoma. Am J Clin Oncol. 1988;11:465-469.
2. Taylor CW, Chase EM, Whitehead RP, et al. A Southwest Oncology Group Phase I study of the sequential combination of recombinant interferon-K and recombinant Interleukin-2 in patients with cancer. J Immunother. 1992;11: 176-183.
3. Viens P, Biaise D, Stoppa AM, et al. Interleukin-2 in association with increasing doses of interferon-γ in patients with advanced cancer. J Immunother. 1992;11:218-224.
4. Stevenson FK. Tumor vaccines. FASEB J. 1991;5:2250-2257.
5. Seigler HF, Cox E, Mutzner F, Shepherd L, Nicholson E, Shingleton WW. Specific active immunotherapy for melanoma. Ann Surg. 1979;190:366-372.
6. De Vita V, et al. Biologic Therapy in Cancer. J B Lippincott Company; 1991.
7. Creagan ET, Ahmann DL, Long HJ, Frytak S, Sherwin SA, Chang MN. Phase II study of recombinant leukocyte interferon-α in disseminated malignant melanoma. Cancer Treat Rep. 1987;71:843-844.
8. Quesada JR, Kurzrock R, Sherwin SA, et al. Phase II studies of recombinant human interferon γ in metastatic renal cell carcinoma. J Biol Response Mod. 1987;6:20-27.
9. Mahaley MS, Bertsch L, Cush S, et al. Systemic γ-interferon therapy for recurrent gliomas. J Neurosurg. 1988;69: 826-829.
10. Russo D, Fanin R, Zuffa E, et al. Treatment of Ph+ chronic myeloid leukemia by γ interferon. Blood. 1989;59: 15-20.
11. Von Hoff D, Fleming TR, Macdonald JS, et al. Phase II evaluation of recombinant γ-interferon in patients with advanced pancreatic carcinoma: a Southwest Oncology Group study. J Biol Response Mod. 1990;9:584-587.
12. Boutin C, Nussbaum E, Monnet I, et al. Intrapleural treatment with recombinant γ-interferon in early stage malignant pleural mesothelioma. Cancer. 1994;74:2460-2467.
13. Brown TD, Goodman PJ, Fleming T, et al. Phase II trial of recombinant DNA γ-interferon in advanced colorectal cancer: a Southwest Oncology Group study. J Immunother. 1991;10:379-382.
14. Habif DV, Ozzello L, De Rosa CM, et al. Regression of skin recurrences of breast carcinomas treated with intralesional injections of natural interferons α and γ. Cancer Invest. 1995;13:165-172.
15. Wallach D, Fellous M, Revel M. Preferential effect of γ interferon on the synthesis of HLA antigens and their mRNAs in human cells. Nature. 1982;299:833-836.
16. Siegler HF, Darrow TL, Abdel-Wahab Z, et al. A phase I trial of human γ interferon-transduced autologous tumor cells in patients with disseminated malignant melanoma. Hum Gene Ther. 1994;5:761-777.
17. Cornetta K, Berebitsky D, Behnia M, et al. A retroviral vector expressing human interferon γ up-regulates MHC antigen expression in human breast cancer and leukemia cell lines. Cancer Gene Ther. 1994;1:91-98.
18. Gastl G, Ebert T, Finstad CL, et al. Major histocompatibility complex class I and class II expression in renal cell carcinoma and modulation by interferon γ. J Urol. 1996; 155:361-367.
19. Howard B, Burrascano M, McCallister T, et al. Retrovirus-medicated gene transfer of the human γ-IFN gene: a therapy of cancer. Ann N Y Acad Sci. 1994;716:167-187.
20. Ucar K, Seeger RC, Challita PM, et al. Sustained cytokine production and immunophenotypic changes in human neuroblastoma cell lines transduced with a human γ-interferon vector. Cancer Gene Ther. 1995;2:171-181.
21. Abdel-Wahab ZA, Osanto S, Darrow TL, et al. Transduction of human melanoma cells with the γ interferon gene enhances cellular immunity. Cancer Gene Ther. 1994;1: 171-179.
22. Maraskovsky E, Chen WF, Shortmen K. IL-2 and IFN-γ are two necessary lymphokines in the development of cytolytic T cells. J Immunol 1989;143:1210-1214.
23. Saito T, Berens ME, Welander CE. Direct and indirect effects of human recombinant γ-interferon on tumor cells in a clonogenic assay. Cancer Res. 1996;46:1142-1147.
24. Ratliff TL, Kadmon D, Shapiro A, et al. Inhibition of mouse bladder tumor proliferation by murine interferon-γ and its synergism with interferon-β. Cancer Res. 1984;44: 4377-4481.
25. Maekawa R, Kitagawa T, Hojo K, Sato K. Differential efficacies of recombinant murine interferon-γ and recombinant human interleukin-2 against EL4-bearing mice. J Interferon Res. 1988;8:241-249.
26. Silagi S, Dutkowski R, Schaefer A. Eradication of mouse melanoma by combining treatment with recombinant human interleukin-2 and recombinant murine interferon-γ. Int J Cancer. 1988;41:315-322.
27. Bateman WJ, Fiera R, Matthews N, et al. Inducibility of class II major histocompatibility complex antigens by interferon-γ is associated with reduced tumorigenicity in C3H mouse fibroblasts transformed by v-KI-ras. J Exp Med. 1991;173:193-196.
28. Panelli MC, Wang E, Shen S, et al. Interferon γ (IFN-γ) gene transfer of an EMT6 tumor that is poorly responsive to IFN-γ stimulation: increase in tumor immunogenicity is accompanied by induction of a mouse class II transactivator and class II MHC. Cancer Immunol Immunother. 1996;42:99-107.
29. Watanabe Y, Kuribayashi K, Miyatake S, et al. Exogenous expression of mouse interferon γ cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented antitumor immunity. Proc Natl Acad Sci USA. 1989;89:9456-9460.
30. Gansbacher B, Bannerji R, Daniels B, et al. Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long-lasting antitumor immunity. Cancer Res. 1990;50:7820-7825.
31. + T-cells against the wild-type tumor: correlation with antigen presentation capability. J Exp Med. 1992;175:1423-1431.
32. Porgador A, Bannerji R, Watanabe Y, et al. Antimetastatic vaccination of tumor-bearing mice with two types of IFN-γ gene-inserted tumor cells. J Immunol. 1993;150: 1458-1470.
33. Culver KW. Clinical applications of gene therapy for cancer. Clin Chem. 1994;40:510-512.
34. Schmidt-Wolf GD, Schmidt-Wolf GH. Cytokines and gene therapy. Immunol Today. 1995;16:173-175.
35. Colombo MP, Forni G. Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today. 1994;15:48-51.
36. Gansbacher B, Zier K, Daniels B, et al. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med. 1990;172:1217-1224.
37. Walsh P, Dorner A, Duke RC, et al. Macrophage colony-stimulating factor complementary DNA: a candidate for gene therapy in metastatic melanoma. J Natl Cancer Inst. 1995;87:809-816.
38. Nemunaitis J, Klemow S, Jain V. Gene therapy: clinical applications in hematology and oncology - part II. J Oncol Management. 1996;5:30-37.
39. Rosenthal FM, Cronin K, Bannerji R, et al. Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-γ cDNAs. Blood. 1994;83:1289-1298.
40. McAdam AJ, Pulaski BA, Storozynsky E, et al. Analysis of the effect of cytokines (interleukins 2, 3, 4, and 6, granulocyte-macrophage colony-stimulating factor, and interferon-γ) on generation of primary cytotoxic T-lymphocytes against a weekly immunogenic tumor. Cell Immunol. 1995; 165:183-192.
41. Smiley WR, Laubert B, Howard BD, et al. Establishment of parameters for optimal transduction efficiency and antitumor effects with purified high-titer HSV-TK retroviral vector in established solid tumors. Hum Gene Ther. 1997;8:965-977.
42. O'Malley BW, Cope KA, Chen SH, et al. Combination gene therapy for oral cancer in a murine model. Cancer Res. 1996;56:1737-1741.
43. Kwong YL, Chen SH, Kosai K, et al. Adenoviral-mediated suicide gene therapy for hepatic metastases of breast cancer. Cancer Gene Ther. 1996;3:399-344.
44. Sutton MA, Berkman SA, Chen SH, et al. Adenovirus-mediated suicide gene therapy for experimental bladder cancer. Urology. 1997;49:173-180.
45. Boucher Y, Baxter LT, Jain RK. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res. 1990;50:4478-4484.
46. Cusack JC, Spitz FR, Nguyen D, et al. High levels of gene transduction in human lung tumors following intralesional injection of recombinant adenovirus. Cancer Gene Ther. 1996;4:245-249.
47. Roth JA, Nguyen D, Lawrence DD, et al. Retroviral mediated wildtype p53 gene transfer to tumors of patients with lung cancer. Nat Med. 1996;2:985-991.
48. Fong TC, Chong K, Robbins JM, et al. Regional and systemic cancer therapy by direct intralesional administration of γ-IFN retroviral vector. Cancer Gene Ther. 1996;3: S12.
49. Howard B, Burrascano M, McCallister T, et al. Retrovirus-mediated gene transfer of the human γ-IFN gene: a therapy for cancer. Gene Ther Neoplastic Diseases. 1994; 716:167-187.
50. Nabel GJ, Gordon D, Bishop DK, et al. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-lyposome complexes. Proc Natl Acad Sci USA. 1996;93:15388-15393.
51. Nabel GJ, Nabel EG, Yang ZY, et al. Direct gene transfer with DNA-liposome complex in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA. 1996;90:11307-11311.
52. Rubin J, Galanis E, Pitot HC, et al. Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7. Gene Ther. 1997;4:419-425.
53. Trono D. Partial reverse transcripts in virions from human immunodeficiency and murine leukemia viruses. J Virol. 1992;66:4893-4900.
54. Lew D, Parker SE, Latimer T, et al. Cancer gene therapy using plasmid DNA: pharmacokinetic study of DNA following injection in mice. Hum Gene Ther. 1995;6:553-564.
55. Nemunaitis J, Bohart C, Fong T, et al. Phase I trial of retroviral vector-mediated interferon-γ (IFN-γ) gene transfer into autologous tumor cells in patients with metastatic melanoma. Cancer Gene Ther. 1998;5:292-300.